Your Strategy For Winning The War On Cancer

Sylvie Beljanski

Thank you so much for having me. I am delighted. It is not my first time, and it is a great pleasure to come to your program.

Michael Karlfeldt, ND, PhD

Well, I love it then. Each time I buy, we chat. You look gorgeous. Each time. For all of you out there, Sylvie Beljanski is a French lawyer by trade. She’s a health advocate for holistic medicine. Public speaker. Internationally known author and entrepreneur. She is the founder and executive vice president of the Beljanski Foundation. Her mission is to research natural approaches to cancer. She’s also the CEO of Maison Beljanski, an international dietary supplement company. Sylvie Beljanski is the award-winning author of Winning the War on Cancer: The Epic Journey Towards a Natural Cure, which has been translated into French under the title Gagner La Lutte Contre Le Cancer. How did I do it?

Sylvie Beljanski

Gagner La Lutte Contre Le Cancer.

Michael Karlfeldt, ND, PhD

I wanted to see how much I butchered that. This book has helped propel me, and this is just a sought-after speaker at health and wellness conferences globally, where she educates thousands of people about scientific breakthroughs in the field of integrative medicine. It’s tremendous what you’re doing. I know we’ve had time to chat in private. You’re doing a lot with a very slim group of people. Yes. There’s a lot of effort that you’re having to put in on your own and driving this forward tremendously.

Sylvie Beljanski

But I have a very small but effective, very dedicated group of people that I am working with. They strongly believe in what we are doing and the mission of the foundation, and therefore they give their best daily to this research program. We know that we make a difference. We see it every day. It is good for the heart. It is a labor of love daily. But it makes us very proud and very happy.

Michael Karlfeldt, ND, PhD

We are so blessed by your effort. I know that the supplements that your campaign provides, the OnKobel-Pro and the Immunobel-Pro, are supplements that I continually use for my cancer patients here at my center. It is a great benefit just to have those available. That research came out of the years and years of studying and scientific research that your father did in France.

Sylvie Beljanski

Thank you for your kind words and for trusting in our products. It means a lot, of course. We do need this support to be able to carry on with the research at the Beljanski Foundation. The Beljanski Foundation is separated from the company, Maison Beljanski. Maison Beljanski makes the number of products available. You mentioned two of them. Those are exclusively available for health professionals. More products are certified that you can buy over the counter. We have also, separately, defined governance. The Beljanski Foundation, which has 501(c)(3) status, was incorporated in 1999 in New York and has been working over the years with us, establishing partnerships with some universities that are doing some research, and that way of working and delegating the research allowed us to cover a lot of grants and also program research, which led to peer-reviewed papers that are all made available to all on the website of the foundation, beljanski.org. We are all about funding research in the field of integrative medicine and sharing all this information for free. We see everybody because that is what a non-profit should do.

Michael Karlfeldt, ND, PhD

Sylvie, what are certain targets within the research that you’re doing? Is cancer one of the targets that you’re closely following?

Sylvie Beljanski

We are not exclusively but mostly working on seeing how many plant extracts have been able to beat the development of cancer cells in mice. That is what we have been able to achieve. My father, Dr. Mirko Beljanski, was a Ph.D. in molecular biology and was working at the Pasteur Institute in Paris. He was one of the first scientists to look at the environment as a cause of disease when it is polluted. At that time, everybody was thinking that cancer could only be a genetic disease. If it was only resulting from some random mutation or genetic mutation in a gene, my father said that maybe mutation happens sometimes, but something is happening as an event of the DNA when we are in a polluted environment, and he was able to measure the degree of destabilization of the DNA in the presence of some environmental toxins. Then he looked for natural compounds that would do exactly the opposite, meaning this prevents the destabilization of the DNA, all specifically preventing the course of destabilized DNA, and destabilizing DNA is a hallmark of cancer. Whether you look at the plant kingdom, the animal kingdom, or humans, every time cancer shows the same way an invasion of the DNA in a microscope, a cell that stands cancerous exhibits DNA, whereas the two branches of the DNA are not kept well together. There are some big openings. What my father called big loops is that when you have those big loops, the replication hormones have plenty of space to access the replication sites, and then you have an increased duplication of websites. That is how we measure the level of destabilization. We found some non-tech stocks that recognize those big loops, and any beating of this destabilized DNA will cause it to grow and multiply.

Michael Karlfeldt, ND, PhD

Just to kind of see if I get this straight, so you have the gene and the DNA strands, and then they should be tightly woven, and that will then regulate the kind of space that hormones or different replication stimulation can come in. It will kind of control that. But in cancer, they are kind of loosely woven in some way. You have these big loops, which will then create more space for these hormones and other kinds of stimulation factors to increase the replication of that genetics because of these loops. There are then plants that he was able to find in a kind of block where those loops existed so that it could not be stimulated as is. That is what I understand.

Sylvie Beljanski

It is specifically designed to recognize those big loops, and it can enter those cells and the nucleus of those cells specifically. Then it induces apoptosis as a mechanism of action in this story.

Michael Karlfeldt, ND, PhD

That is fascinating. With the research that you’re doing, what have you seen? What kind of results are you seeing? Are there specific cancers you’re targeting in regards to this? Or are there more broad ones or several ones?

Sylvie Beljanski

The beauty of that is first what is specific to cancer in a sense, and then it goes to all the concepts of cells. So, healthy cells are untouched. It is when you have tightly woven DNA. The product is never going to come across, and he’s not going to enter any cells. It is going to be just fine, which means no toxicity and no side effects. You are good. If you do not have any cells with destabilized DNA, you are going to eliminate the product in a matter of hours. But if you have cells with destabilized DNA, which again is a hallmark of cancer, it is going to reach all those cells wherever they are located. You stop thinking of lung cancer, prostate cancer, ovarian cancer, and pancreatic cancer. It does not matter. You have cells whose DNA destabilizes or not. You have a very broad application with the same plant extracts. It has no toxicity, no side effects, and no toxicity to healthy cells. It is going to reach out to all the cancerous cells, whatever kind of cancer we are speaking about. What we have been able to see over the past few years is that we are working with Columbia University and the Kansas University Medical Center, for example. It is a different kind of cancer because, in the lab, you have to choose which cells you are going to work with. However, we were able to confirm that we had similar and great results on prostate cancer, ovarian cancer, and pancreatic cancer. Now, some other teams around the world who have become interested in this project are also concerned about colon cancer and oral cancer, and we have done research recently on melanoma. The number of applications seems to be endless for as many organs as we have.

Michael Karlfeldt, ND, PhD

These were then your father, as he was researching; he was, I mean, looking for all these different chemicals out there that existed and then were able to isolate these chemicals. Within these plant extracts, correct?

Sylvie Beljanski

He first looked for and created a database of toxins that destabilize the DNA. He is so obsessed that his database would be of great interest to people making products and manufacturing resources around the world, so they could avoid carcinogens. But of course, a lot of manufacturers do not want to take their products off the market just because there is a researcher somewhere who says that there is a carcinogen in them. They just tried to ignore him and silence him. My father went on looking for those natural compounds that would act exactly as environmental toxins. He found some small anti-carcinogen compounds. Nature has a lot of anti-carcinogens. Nature is about bountiful, but some more power for and causes some. My father was keen on having products that would be selective, meaning they would not harm anyone. That was important to him and to me now because how would you make compounds, foods, and products and put them on the market knowing that there could be some risk somewhere? One of the successes of what we have been doing, of course, is the fact that there is no toxicity associated with the products or with those extracts.

Michael Karlfeldt, ND, PhD

He found them, and they looked up these chemicals that could cause cancer and create that destabilization. He was looking for natural products that had the opposite effect. What were some of the things that he found—some natural substances that had that effect on me? Which ones were kind of rated at the top of the list to have that effect from all this research?

Sylvie Beljanski

In the first research, a plant extract that was quite well-known at the time was very well-documented in Ayurvedic medicine. It is called Rauvolfia. The problem with Rauvolfia was that it has a beneficial compound that’s earned the reputation of Rauvolfia as an anti-blood pressure product, but it is also linked to or known to induce breast cancer. My father studied those extracts, and he was able to isolate the compounds that induce cancer and remove them from the Rauvolfia extract. He is Rauvolfia, his preparation. His preparation of Rauvolfia is completely reserpine-free and rich in alstonine. And alstonine has these beautiful selective anti-cancer properties that it approaches in several cancerous cells, and the purification process of the rauvolfia is very messy and expensive.

You lose a lot of product when you remove the reserpine. You looked at it to see if he could find a molecule that would be close to alstonine, which he found in the box, flavopereirine. And then his work was to find plants in nature that would contain flavopereirine. He found the Pao Pereira, which comes from South America. It is a big tree. One of the benefits of the tree is that it does not need to be cut down to recover the bark of the tree. You can just shave some bark. As long as you leave 20% of the bark of the tree, it will regrow itself. It is a very sustainable approach. On top of being natural, the extract comes back once again as selective, meaning no toxicity to healthy cells. And an anti-cancer effect on all the cancerous cells.

Michael Karlfeldt, ND, PhD

That’s fascinating. Is that part of one of your extracts from OnKobel?

Sylvie Beljanski

On OnKobel, you have the Pao pereira extract, the Rauvolfia vomitoria extract, and also a specific extract of Golden Gingko. Golden gingko is made of golden leaves. It is the same gingko tree, but when in the soil the chemistry of the leaves changes, translating to a change in color of the leaves, and then the same becomes rich in the different substances that green gingko extracts that you find everywhere and a golden gingko extract with the rarest specific extraction procedure that does not include any solvent. It’s just water-based. It can promote collagen production in the liver, help repair wounds, and prevent fibrosis that can result from radiation. The latest research programs that we have and this ginkgo-specific, gingko extract show that it helps inhibit l-arginine, an enzyme that helps cancerous cells create additional blood vessels to feed them. The cancer cells need a lot of energy, so they need a lot of nutrients. They create additional blood vessels to bring more food to themselves. With the Golden Ginkgo, we can stop those cancerous cells, which is kind of an indirect way to get rid of them. In addition to the apoptosis induced by Pao Pereira and Rauvolfia vomitoria, combining the two makes sense and delivers good results.

Michael Karlfeldt, ND, PhD

That is amazing, and what’s incredible is that these are things that are being researched at a university like Columbia University, where this has been proven to take place in studies.

Sylvie Beljanski

Yes. My father left 133 peer-reviewed papers in reputable magazines. We needed to get a young guy in his name with his name and his legacy to also work with extremely reputable institutions. There is no discussion. The people are not going to prove the science. You want to make sure that these labs and those universities, reputable universities, are excited at the idea of working on those little-known extracts because it is exciting for researchers to do something that is new and is going to attract the interest of scientific teams around the world. Again, Pao Pereira, for example, and Flavopereirine, for example, as other teams around the world, are publishing different applications regularly.

Michael Karlfeldt, ND, PhD

Yes, and this has been the challenge, so when you deal with natural substances, you have to get funding for this type of research because research is not inexpensive. Universities know their labs and their staffing, and all of these things do cost money.

Sylvie Beljanski

It is a horrendous cost. Yes. But that is why we are doing that, which is why we are non-profit. I am grateful for all the support that the foundation has received. Those five manufacturers cannot make claims. If they cannot make claims, the manufacturers of dietary supplements have no incentive to fund research as they are not going to be able to speak about it. It is a kind of vicious cycle. You don’t research because you are not going to be able to exploit it and make claims. You should not make claims about that. Make some friends and spend the money on research.

Michael Karlfeldt, ND, PhD

How do you walk that line between being a dietary supplement protected under the DSE ACT (Dietary Supplement Education Act) versus being classified as a drug or pharmaceutical that has to be prescribed?

Sylvie Beljanski

There are two things. One, I try as much as possible to make the difference between the foundation doing so much research and the company. I mean, you will not find any claim on the website of the company, Maison Beljanski, that is outrageous; you will not find anything or so on. As neighbors of such products, we are careful not to cause any offense. The other thing is that, if you look at the CDC, and thank you for mentioning it, there is a provision in the DOJ saying that you cannot claim unless you have been notified. You cannot research claims unless you have notified the FDA before doing research.

Michael Karlfeldt, ND, PhD

Oh, okay.

Sylvie Beljanski

If you first notify the researcher, as in notifying the separate ingredient for supplement use, then there is no evidence that, at that time, you had any intent to research ingredients for research purposes.

Michael Karlfeldt, ND, PhD

Oh, yes. That is where it helps to be a lawyer. Correct.

Sylvie Beljanski

When do you have to learn how to look at the text on different dates? One could say it is a loophole, but it is there. If you start by notifying the ingredient, then you are free to do some research later.

Michael Karlfeldt, ND, PhD

Another product that I love is that you have, cancer patients, many of them choose to use both natural means to support the body and, at the same time, conventional therapies like surgery, radiation, and chemotherapy. Each individual has to decide what feels right to them as to how much they want to lean in both directions. The beauty is that these products will not subtract from the efficacy of conventional therapies. Correct.

Sylvie Beljanski

What we have seen and my father was already speaking of that, but we had to do the scientific research again because chemotherapies nowadays are not the same molecules that were used at the time of my father. But he was, and that was his time. Speaking already of the synergy of action between chemotherapy bees and helping on our show when we go here, and what we have seen with modern molecules like gemcitabine, and carboplatin, is that there is this synergy of action. We saw that also with docetaxel. Different teams at Columbia University, including gemcitabine and carboplatin, were responsible for this work at the University Medical Center. That is very interesting because gemcitabine, carboplatin, and docetaxel are different molecules, and sometimes you cannot associate them together. They want to work together. However, every time there is a nice synergy of action, we fall behind.

Michael Karlfeldt, ND, PhD

That is amazing. One of the challenges I know that people are facing while going through these therapies is that their white blood cell count goes down, their hemoglobin goes down, and then they have to stop or pause their conventional therapies just to get their blood numbers to rebound. In our clinic, we use things like Immunobel-pro to help support them.

Sylvie Beljanski

That is a completely different line of research. But it also stems from one of my father’s discoveries he wanted: he was looking at how to help people with cancer and how one of the side effects of chemotherapy is very often, as you said, the destruction of blood cells, and white blood cells are very often a casualty of chemotherapies. My father said, “Okay, so how is the body naturally making those white blood cells?” What is now made by the bone marrow? How can we support the bone marrow in its work? He’s doing his job, and he was able to affect those little, tiny fragments that are specific to, like, primers for the synthesis of the DNA of the bone marrow. It has to be very, very specific because you don’t want to claim anything less than the DNA of the bone marrow, which is going to make those white blood cells. It was able to come up with those little RNA fragments. They come from bacteria that are naturally present in the gut. There is no risk of complications. It is not a pathogen; it is not mutagenic.

It is completely purified. We only keep those little RNA fragments, and it is a shortened version of what is happening in the body because in the body it is in the gut that we are creating. What we need are nutrients that are going to be absorbed by the blood, and the blood will go to the bone marrow. That is, instead of waiting to be sure that we have what it takes in the gut and that we know that the lining of the body is often also damaged, chemotherapy is sent. You take those little RNA filaments already prepared on the desert dog, so it goes directly as quickly as possible without being dehydrated by the enzyme. The saliva goes directly to the blood, and then it will do what it is supposed to do. Support your bone marrow by creating a decent number of white blood cells. A decent number is very important because you don’t want to create too much.

You just want to have a physiological number, and that is, we have never seen too much. The body regulates itself very nicely with this product and creates a large number of white blood cells. What is interesting about working by just boosting and supporting the bone marrow is that the bone marrow creates a lot of different kinds of white blood cells. It is so that white blood cells are like a little army where every soldier knows what he has to do to protect himself and our immune system. Bone marrow creates all the army, or the soldiers, and delivers everything. If you take a synthetic product, and there are some synthetic products out there that are going to help with one family of cells, then you are at risk of creating an imbalance, which never happens when you have just got a body to keep you on track.

Michael Karlfeldt, ND, PhD

This craves the full spectrum of these different intelligent components that are needed to do the job fully. Because you need all, it is like trying to run a company with just accountants.

Sylvie Beljanski

Yes, exactly.

Michael Karlfeldt, ND, PhD

You need all the components to be able to run everything effectively. Just because you have a bunch of bodies and a bunch of accountants does not mean that the company is going to run effectively.

Sylvie Beljanski

Yes. You don’t want to create another imbalance. You want to have a cow once and for weeks.

Michael Karlfeldt, ND, PhD

And this has been part of the research as well, through the foundation or what?

Sylvie Beljanski

Yes. Then we were very lucky. We had a clinical trial a few years ago with Cancer Treatment Centers in America, but we saw those little fragments of RNA, the population subjected to the clinical trial, where patients suffering from different kinds of cancer, different stages of cancer. What they had in common was that they were all on the verge of thrombocytopenia. At the verge, technically, they did not have thrombocytopenia; they were at the limit, and they were all expected to fall into thrombocytopenia, which is a lack of white blood cells or platelets, which are linked to the white blood cells. If nothing was done and they had more rounds of chemotherapy, they were all expected to develop. thrombocytopenia. Lack of platelets, which are a family of one of the soldiers created by the blood cells, helps prevent bruising. It is the compound that helps it clot. If you do not clot properly, you can lose a lot of blood, which creates a lot of problems. This is a common side effect of some chemotherapy. They were very eager at the Cancer Treatment Centers of America to see four little compounds. We saw toxicity; we saw side effects that could prevent this thrombocytopenia from developing, and all of the patients in the hall were able to avoid thrombocytopenia. None of them developed the disease. None of them needed transfusions. You could see that even when you stopped giving them, those were RNA fragments. They were able to do it by themselves, and bone marrow was able to create more platelets than at the beginning of the cycle. The bone marrow had been kind of protected and somewhat repaired during the cycle of chemotherapies.

Michael Karlfeldt, ND, PhD

That is incredible. Where can people go to learn about all these studies? Where can they find them?

Sylvie Beljanski

All the publications are available on the website beljanski.org. That is where you have information about both my father’s work and recent publications, as well as all the events because we are hosting several educational events regularly to share information about this research.

Michael Karlfeldt, ND, PhD

In addition to obviously going to the events, people also have the opportunity to donate to the foundation to support this type of research.

Sylvie Beljanski

Yes. Anyone who donates to the foundation also gets invitations to the events and the regular newsletters, explaining how we use the money and sharing everything about how the new business works. I mean, we have about two kids, and here is a paper we share with you. So how is your money used? And this is something I found: a lot of people are giving to kind of well-known foundations because they have done something good and they have a tax-to-tax paper to avoid taxes they think is in order. But then you asked them, so what has changed? How has the money been used? Oh, we hope it was good for a good cause and a good use. But people don’t follow up on how the money is used. I do feel it is important to share with people. Also good results that we get regularly, and let them know what’s our funding and exactly which research programs are funded. We are now trying to fund new research on breast cancer stem cells. Sounds very specific, but cancer stem cells are those cells that resist chemotherapy and stay in the blood doing that kind of conventional concert treatment, and they are linked to metastasis and relapse, a conventional medicine.

As of today, there is nothing to fight cancer stem cells. When it comes to breast cancer, about 30% of breast cancer survivors will probably suffer from relapses. It does not mean that we die of even just skin cancer; it means that we are living with it, which is anxiety all the time, which is eating our quality of life, and its feelings that we are like sitting ducks waiting for that cancer stem cells to create havoc somewhere else in the body. With support behind us when we say yes, which is so effective against so many cancerous kinds of cells, and also dish on stages of cancer because we were able to, there’s hope in, for example, BPH, which is a very early stage. It’s just that it is still benign, but it is an inflammation of prostate cells, and this inflammation can eventually lead to cancer. Then we also tested Rauvolfia vomitoria on full-blown cancer cells with great success. We have had a study on advanced prostate cancer cells that do not respond anymore to monotherapy, and we were able to analyze the mechanism of action inhibition of NF-kappa B to also prevent that from developing. We said, Why not test those little extracts on cancer stem cells? We have already tried it on ovarian and pancreatic cancer and stem cells in vitro and in vivo, and it works.

Michael Karlfeldt, ND, PhD

How is that measured? How were you able to kind of recognize that it did have an impact on cancer stem cells?

Sylvie Beljanski

Cancer stem cells offer different shapes, like those that you can recognize under the microscope. Researchers are able, for example, to cauterize them and see if they develop or not. In mice, you induce a certain kind. You inject those cancer stem cells into a mouse, and you see the tumor grow. You give the plant extracts, and you see what happens. We saw that before the animal study. We used only gavage, meaning taking by mouse, and a similar dose to what a human can take when taking supplements. We have a reason that we can extrapolate that could have a similar effect on humans because if you go intravenously, which is very often done with animals, then you have something that actually cannot translate to the use done for humans, at least by mice.

Michael Karlfeldt, ND, PhD

That is exciting. Well, it is so exciting. That is what I love in regards to integrative oncology and the holistic cancer space—that there’s so much going on in so many different areas. That is why I love doing this summit: I get to chat with people like yourselves who are driving this field forward, and it is being done in so many places in so many different ways. I so appreciate all of us coming together to bring to light the solution to something that the medical profession hasn’t been able to solve since it declared war on cancer.

Sylvie Beljanski

That is why we are still in the war on cancer. But my vision for that is looking at the right place, and that is why the war never ends. Some people love to be at war because they are making money.

Michael Karlfeldt, ND, PhD

That is why we need to shift strategy to maybe become successful rather than just making money and being at war.

Sylvie Beljanski

Doing the same thing again and again is a definition of insanity.

Michael Karlfeldt, ND, PhD

I love it. Well, Sylvie, it is a pleasure. Thank you so much for everything that you’re doing. Thank you so much.

Sylvie Beljanski

Thank you so much.